Oncology trial share with biomarkers to personalize treatment 2000-2019
During the shown period, the share of clinical trials in oncology which targeted biomarkers to personalize cancer treatment, has increased from approximately 18 percent in 2000 to 61 percent in 2019. Personalized medicine is a fast growing market, driven by significant technology advances like, for example, in the area of genome sequencing.